John Abraham: Breaking the ‘Bleeding Disorder’ Myth About Cirrhosis and Coagulation
John Abraham, Assistant Professor at Christian Medical College and Hospital, shared a post on Linkedin about a recent article by Conor Bell published in Journal of Thrombosis and Haemostasis, adding:
“Cirrhosis and Coagulation — Beyond the ‘Bleeding Disorder’ Myth
For years, we were taught that cirrhosis meant a bleeding tendency.
But evolving evidence tells a very different story.
Paper: Prevention and treatment of thrombosis in patients with decompensated cirrhosis
Journal: Journal of Thrombosis and Haemostasis (JTH), 2026
Authors: Conor Bell, Amber Afzal, Stephanie Carlin, Lara N. Roberts
DOI: 10.1016/j.jtha.2025.12.018
The Core Concept: Rebalanced Hemostasis
Cirrhosis leads to a ‘simultaneous decline in procoagulant and anticoagulant factors’, creating a fragile equilibrium—not a hypocoagulable state.
- Decreased Factors II, V, VII, IX, X
- Decreased Protein C, Protein S, Antithrombin
- Increased von Willebrand factor
- Decreased ADAMTS13
Net effect: A system that can tip toward bleeding or thrombosis
Why Conventional Thinking Fails
- INR reflects only procoagulant deficiency and therefore overestimates bleeding risk
- Platelet count does not capture compensatory mechanisms (increased vWF)
- Standard labs isn’t true hemostatic balance
Mechanistic Insights
- Endothelial activation creates a prothrombotic milieu
- Platelet count is reduced but function relatively preserved
- Fibrinolysis is dysregulated (both hyper and hypo states)
- Portal hypertension is the major driver of bleeding
Clinical Reality
- High Risk of stroke (AF)
- High risk of VTE (2× risk)
- High Risk of Portal vein thrombosis
At the same time:
Bleeding risk is real—but largely ‘portal hypertension–driven’, not purely coagulopathic
Take-Home Message
Cirrhosis is not a bleeding disorder.
It is a ”rebalanced but unstable’ hemostatic state’.
This paradigm shift is crucial when:
- Deciding on anticoagulation
- Interpreting INR/platelets
- Managing PVT or AF
As clinicians, the challenge is no longer ‘Should we anticoagulate?’ but ‘Who, when, and how safely?’”
Title: Prevention and treatment of thrombosis in patients with decompensated cirrhosis
Authors: Conor Bell, Amber Afzal, Stephanie Carlin, Lara N. Roberts
Read the Full Article on Journal of Thrombosis and Haemostasis
Stay updated with Hemostasis Today.
-
Jul 5, 2026, 02:45Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
-
Jul 5, 2026, 02:24Shreya Agarwa: Transforming Care For Adolescents With Heavy Menstrual Bleeding
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders